Skip to main content
# Title Research Year
81 The Efficacy of Denosumab versus Zoledronic Acid in Preventing
Skeletal Related Events in Cancer Patients with Bone Metastasis
2017
82 Technetium-99m pentavalent dimercaptosuccinic acid (99mTc-DMSA-V) brain SPECT/CT and Karnofsky performance score predict survival in patients with glioma 2017
83 Gemcitabine plus Paclitaxel versus Paclitaxel Monotherapy in
Patients with Metastatic Breast Cancer
2017
84 Brain SPECT/CT scanning with technetium-99m pentavalent dimercaptosuccinic acid [DMSA (V)] is an accurate tool for post-treatment evaluation of patients with glioma. 2017
85 Gemcitabine plus Paclitaxel versus Paclitaxel Monotherapy in
Patients with Metastatic Breast Cancer
2017
86 Brain SPECT/CT scanning with technetium-99m pentavalent dimercaptosuccinic acid [DMSA (V)] is an accurate tool for post-treatment evaluation of patients with glioma. 2017
87 The Prognostic Impact of Neutrophil Lymphocytic Ratio (NLR)
o n
Survival of Patients with Glioblastoma Multiforme (GBM): A
Retrospective Cohort Study
2017
88 Technetium-99m pentavalent dimercaptosuccinic acid (99mTc-DMSA-V) brain SPECT/CT and Karnofsky performance score predict survival in patients with glioma
2017
89 The Prognostic Impact of Neutrophil Lymphocytic Ratio (NLR)
o n
Survival of Patients with Glioblastoma Multiforme (GBM): A
Retrospective Cohort Study
2017
90 Technetium-99m pentavalent dimercaptosuccinic acid (99mTc-DMSA-V) brain SPECT/CT and Karnofsky performance score predict survival in patients with glioma
2017